SAN DIEGO, CHRON Volcano Corporation today announced its participation in the Paris course for Revascularization (EuroPCR) from May 17 — 20. Volcano's focus will be on highlighting the strength of its ...

On Thursday during a Hotline / Late-Breaking Trials session, Dr. Toru Tanigaki of Gifu Heart Center in Gifu, Japan, will present the one-year results of the PROVISION 1 Study, the first-ever Japanese ...

THE ANNUAL world-leading course in interventional cardiology, EuroPCR, welcomed 12,147 participants to Paris, France, for a dynamic ...

NEW YORK, NY – The Cardiovascular Research Foundation (CRF) will hold a special session providing updates on several key cardiovascular trials on Tuesday, May 20 at this year’s EuroPCR meeting. The ...

Over 11,000 participants from around the globe are once again expected at EuroPCR – a Course tailored for interventional cardiologists, cardiac surgeons, imaging specialists, radiologists, nurses, ...

New Data Reinforces Safety Profile of Abbott’s Market-Leading XIENCE V Drug Eluting Stent: In XIENCE V USA Study, XIENCE V Demonstrates Low Blood Clot Rate at One Year in Real-World Patient Population ...

PARIS, FRANCE – No one could accuse EuroPCR 2014 of giving up on renal denervation following the negative results of the only large, randomized, sham-controlled trial of this cutting-edge technology.

During EuroPCR 2014, Felix Mahfoud, University Hospital in Homburg, Germany, and Konstantinos Tsioufis, University of Athens, Greece, reflected on the potential future role of modulation of the ...

Paris, France: Ongoing development of bioresorbable stent (BRS) technologies that are bioresorbed after achieving vessel expansion in percutaneous coronary intervention procedures is an important ...

At the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference in Washington, DC, investigators from Gifu Heart Center and Fukuoka Sanno Hospital ...